Senzime (SEZI) Q3 2025 earnings summary

Executive summary

• Achieved 80% revenue growth in constant currencies for Jan–Sept 2025, with strong expansion in the US and Europe.

• Sensor deliveries grew 78% year-over-year, driven by increased TetraGraph monitor installations.

• EBITDA improved by 20% year-to-date, with a loss reduction of SEK 15.9 million over nine months.

• Secured major contracts with leading US hospital systems and the US Department of Defense.

• Strategic deals, regulatory approvals in Mexico and Japan, and new software launches enhanced market position.

Financial highlights

• Net sales for Q1–Q3 2025 reached SEK 75.7 million, up 70% year-over-year.

• Gross margin (excluding amortization) at 62.9% YTD, impacted by US tariffs and currency effects.

• EBITDA improved by 20% to -63.8 MSEK YTD; Q3 EBITDA improved by 8% to -19.4 MSEK.

• Cash position at end of Q3 was SEK 106.6 million.

• Earnings per share for Q1–Q3 was -0.66 SEK.

Outlook and guidance

• Confident in delivering within the full-year 2025 sales range in constant currencies despite exchange rate fluctuations.

• Operating expenses expected to rise by a single-digit percentage in 2025, mainly due to US commercial investments.

• Price adjustments in the US and potential production relocation are planned to mitigate tariff impacts.

• Continued focus on profitable growth, recurring revenues, and cost discipline.